VERACYTE, INC. Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent
VERACYTE, INC. (VCYT) reported Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent of $27.88 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent · last filed 2026-02-26
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-12-31 was $8.00K.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-09-30 was $3.74M, a 59.92% decline year-over-year.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-06-30 was $16.68M.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for the quarter ending 2025-03-31 was $7.45M.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2025 was $27.88M.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2024 was -$12.07M, a 264.74% decline from fiscal 2023.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2023 was $7.33M.
- VERACYTE, INC. other comprehensive income (loss), net of tax, portion attributable to parent for fiscal 2022 was -$16.26M.
| Period end | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2025-12-31 | $8.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.75M derived: sum of 2 quarters · filed 2026-02-26 | $20.43M derived: sum of 3 quarters · filed 2026-02-26 | $27.88M 10-K · filed 2026-02-26 |
| 2025-09-30 | $3.74M 10-Q · filed 2025-11-05 | $20.42M derived: sum of 2 quarters · filed 2025-11-05 | $27.87M 10-Q · filed 2025-11-05 | $13.06M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-30 | $16.68M 10-Q · filed 2025-08-07 | $24.13M 10-Q · filed 2025-08-07 | $9.32M derived: sum of 3 quarters · filed 2026-02-26 | $18.65M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-31 | $7.45M 10-Q · filed 2025-05-08 | -$7.36M derived: sum of 2 quarters · filed 2026-02-26 | $1.97M derived: sum of 3 quarters · filed 2026-02-26 | $266.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | -$14.81M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$5.48M derived: sum of 2 quarters · filed 2026-02-26 | -$7.18M derived: sum of 3 quarters · filed 2026-02-26 | -$12.07M 10-K · filed 2026-02-26 |
| 2024-09-30 | $9.33M 10-Q · filed 2025-11-05 | $7.63M derived: sum of 2 quarters · filed 2025-11-05 | $2.74M 10-Q · filed 2025-11-05 | $12.91M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$1.70M 10-Q · filed 2025-08-07 | -$6.59M 10-Q · filed 2025-08-07 | $3.59M derived: sum of 3 quarters · filed 2026-02-26 | -$2.83M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | -$4.89M 10-Q · filed 2025-05-08 | $5.29M derived: sum of 2 quarters · filed 2026-02-26 | -$1.12M derived: sum of 3 quarters · filed 2026-02-26 | -$2.04M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.77M derived: sum of 2 quarters · filed 2026-02-26 | $2.85M derived: sum of 3 quarters · filed 2026-02-26 | $7.33M 10-K · filed 2026-02-26 |
| 2023-09-30 | -$6.41M 10-Q · filed 2024-11-07 | -$7.33M derived: sum of 2 quarters · filed 2024-11-07 | -$2.85M 10-Q · filed 2024-11-07 | $19.87M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-06-30 | -$917.00K 10-Q · filed 2024-08-07 | $3.56M 10-Q · filed 2024-08-07 | $26.28M derived: sum of 3 quarters · filed 2025-02-28 | $10.27M derived: sum of 4 quarters · filed 2025-02-28 |
| 2023-03-31 | $4.48M 10-Q · filed 2024-05-08 | $27.20M derived: sum of 2 quarters · filed 2025-02-28 | $11.18M derived: sum of 3 quarters · filed 2025-02-28 | -$6.18M derived: sum of 4 quarters · filed 2025-02-28 |
| 2022-12-31 | $22.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | $6.70M derived: sum of 2 quarters · filed 2025-02-28 | -$10.66M derived: sum of 3 quarters · filed 2025-02-28 | -$16.26M 10-K · filed 2025-02-28 |
| 2022-09-30 | -$16.02M 10-Q · filed 2023-11-08 | -$33.38M derived: sum of 2 quarters · filed 2023-11-08 | -$38.98M 10-Q · filed 2023-11-08 | -$45.93M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-06-30 | -$17.37M 10-Q · filed 2023-08-09 | -$22.97M 10-Q · filed 2023-08-09 | -$29.91M derived: sum of 3 quarters · filed 2024-02-29 | -$38.05M derived: sum of 4 quarters · filed 2024-02-29 |
| 2022-03-31 | -$5.60M 10-Q · filed 2023-05-05 | -$12.54M derived: sum of 2 quarters · filed 2024-02-29 | -$20.68M derived: sum of 3 quarters · filed 2024-02-29 | |
| 2021-12-31 | -$6.94M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | -$15.08M derived: sum of 2 quarters · filed 2024-02-29 | -$15.08M 10-K · filed 2024-02-29 | |
| 2021-09-30 | -$8.14M 10-Q · filed 2022-11-03 | -$8.14M 10-Q · filed 2022-11-03 | ||
| 2020-09-30 | -$4.12M 10-Q · filed 2021-11-09 | -$26.86M 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| Fulgent Genetics, Inc. (FLGT) | United States | $0.593B | -6.70 |
| BIODESIX INC (BDSX) | United States | $0.312B |